Compare CDMOs with formulation development expertise for oral, injectable, topical, and inhalation dosage forms. Filter by technology platform, therapeutic area, and regulatory support.
620 companies listed
Is your molecule barely soluble? You're not alone. Most new chemical entities in the pipeline are, and formulation is where that problem gets solved or shelved. Formulation development takes an API and makes it stable, absorbable, and manufacturable at scale. It starts with pre-formulation (solubility, stability, excipient compatibility), and it sets the ceiling on your drug's clinical performance. Get it wrong and a promising molecule stalls. The capability that separates a real formulation CDMO from a general one is bioavailability enhancement. Ask what enabling platforms they run in-house: spray-dried dispersions, hot melt extrusion, nano-milling, lipid-based systems, cyclodextrin complexation. One platform isn't enough, because the right approach depends on your compound's physicochemistry. Engage early, ideally in late discovery. Late-stage formulation changes are expensive, and they eat months. 620 CDMOs here offer formulation development. Compare them by platform, dosage form, and therapeutic area.
Formulation development transforms an API into a stable, bioavailable, and manufacturable dosage form. It begins with pre-formulation studies (solubility, stability, compatibility) and progresses through prototype development, optimization, and scale-up. The formulation defines the drug product's clinical performance, and poor formulation choices can doom an otherwise promising molecule.
Bioavailability enhancement is the fastest-growing formulation challenge. An estimated 70-90% of new chemical entities in development pipelines have poor aqueous solubility. CDMOs with expertise in enabling technologies -- amorphous solid dispersions (spray drying, hot melt extrusion), lipid-based drug delivery systems, nanoparticle milling, and complexation -- can rescue molecules that would otherwise fail.
Portugal
Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970, with an industrial unit that has provided contract manufacturing services for over 20 years. The company manufactures non-sterile solid, semi-solid, and liquid pharmaceutical products for third-party clients, offering turnkey and custom services including bulk manufacturing, packaging, analytical release, and scale-up support.
Italy
Gruppo Farma Impresa is an Italian contract manufacturer specializing in medical devices based on substances, food supplements, and dermocosmetics, offering private label production (conto terzi) and out-licensing of over 1,000 ready-to-market products. The company provides formulation development, R&D with over 200 new formulations annually, regulatory affairs support, and clinical trial services across multiple therapeutic areas.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.